<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01152242</url>
  </required_header>
  <id_info>
    <org_study_id>0000-168</org_study_id>
    <secondary_id>2010_541</secondary_id>
    <nct_id>NCT01152242</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)</brief_title>
  <official_title>A Two-Part Clinical Trial to Assess Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the within-subject variation in duration of
      action and time-action profile of glargine measured by isoglycemic clamp will be below
      prespecified levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: The within-subject standard deviation in duration of action of glargine (the difference between onset of action and end of action)</measure>
    <time_frame>Baseline and 30 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: The within-subject coefficient of variation in time-action profile of glargine for AUC-GIR (AUC of glucose infusion rate), GIRmax (maximum level of glucose infusion rate), over the duration of action of glargine</measure>
    <time_frame>Baseline and 30 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: The within-subject coefficient of variation in time-action profile of glargine for AUC-GIR and GIRmax over the duration of action of glargine</measure>
    <time_frame>Baseline and 30 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: The within-subject standard deviation in duration of action of glargine (the difference between onset of action and end of action)</measure>
    <time_frame>Baseline and 30 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part I of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part II of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoglycemic Clamp</intervention_name>
    <description>Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: insulin glargine</intervention_name>
    <description>Insulin glargine at 0.4 U/kg</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>LANTUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1:

          -  Patient is a male between 18 to 45 years of age (inclusive) at the prestudy
             (screening) visit

          -  Patient has a clinical diagnosis of type 1 diabetes

          -  Patient must have been treated with insulin since diagnosis and be on a stable dose of
             insulin

          -  Patient has a Body Mass Index (BMI) of &lt;=27 kg/m2 and &gt;18 kg/m2

          -  Patient has been a nonsmoker and/or has not used nicotine or nicotine-containing
             products for at least approximately 6 months

        Part 2:

          -  Subject is a male between 18 to 45 years of age at the prestudy (screening) visit

          -  Subject has a Body Mass Index (BMI) of &lt;=25 kg/m^2

          -  Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing
             products for at least approximately 6 months

        Exclusion Criteria:

        Part 1:

          -  Patient has a history of stroke, chronic seizures, or major neurological disorder

          -  Patient has currently active and untreated clinically significant endocrine,
             cardiovascular, hematological, hepatic, renal, respiratory, or genitourinary
             abnormalities or diseases

          -  Patient has a history of hypertension requiring treatment

          -  Patient has a history of neoplastic disease within the past 5 years

          -  Patient is currently being treated with, or has a history of treatment with any oral
             antihyperglycemic agent

          -  Patient has a history of significant multiple and/or severe allergies

        Part 2:

          -  Subject has a history of stroke, chronic seizures, or major neurological disorder

          -  Subject has a history of hypertension requiring treatment

          -  Subject has a history of neoplastic disease within the past 5 years

          -  Subject has history of diabetes (Type 1, Type 2 or steroid-induced) or family history
             of diabetes mellitus

          -  Subject has a history of hypersensitivity to glargine or any of its inactive
             ingredients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

